| ¿µ¹® | malignant melanoma | ÇÑ±Û | ¾Ç¼ºÈæ»öÁ¾ |
|---|---|---|---|
| ¼³¸í | ÇǺο¡¼ »ý±â´Â ¾ÏÀÇ ÀÏÁ¾. ÁÖ·Î ¹éÀο¡°Ô È£¹ßÇϸç, 50´ë~70´ë¿¡ ¸¹ÀÌ ¹ß»ýÇϰí, ÀþÀº ¿©¼º¿¡°Ô Áõ°¡ÇÏ´Â °æÇâÀÌ ÀÖÀ¸¸ç, ÇǺξÏÁß 1~3%¸¦ Â÷ÁöÇÏ´Â µå¹® º´À¸·Î ÇÇºÎ¿Í ±âŸ ±â°üÀÇ ¸á¶ó´Ñ ¼¼Æ÷°è¿¡¼ À¯·¡ÇÏ´Â ¾Ç¼ºÁ¾¾çÀÌ´Ù. ¿øÀÎÀ¸·Î Àϱ¤³ëÃâ°ú Á÷Á¢ÀûÀÎ °ü°è°¡ ÀÖÀ¸¸ç °¡Á·Àû ¹ß»ýµµ º¼ ¼ö ÀÖ´Ù. |
||
| ¿µ¹® | testicular feminization syndrome | ÇÑ±Û | °íȯ¿©¼ºÈÁõÈıº |
|---|---|---|---|
| ¼³¸í | ÀÌÂ÷¼ºÀåÀ» Æ÷ÇÔÇÏ¿©, ¿Ü¼º±âÀÇ ¹ßÀ°Àº ¿©¼ºÀÌÁö¸¸ °íȯÀÌ Á¸ÀçÇϰí, Àڱðú ÀڱðüÀÌ °áÇ̵Ǿî ÀÖ´Â ³²¼º °ÅÁþ³²³àÇѸöÁõÀÇ ±Ø´ÜÀû ÇüÅÂÀÌ´Ù. À̰ÍÀº Å×½ºÅ佺Å×·ÐÀÇ ÀÛ¿ë¿¡ ´ëÇÑ ¸»´Ü±â°üÀÇ ÀúÇ׿¡ ±âÀÎÇÑ´Ù. |
||
| ¿µ¹® | irritable bowel syndrome | ÇÑ±Û | °ú¹Î¼º´ëÀåÁõÈıº |
|---|---|---|---|
| ¼³¸í | ¹èº¯Àå¾Ö, º¹Åë, º¹ºÎÆØ¸¸ µîÀÇ Áõ»óÀÌ ÀÖÀ¸³ª ±âÁúÀûÀÎ º´º¯ÀÌ ¾øÀ½ÀÌ È®ÀÎµÈ ¿¹¸¦ ÃѸÁ¶óÇÑ ÀÓ»ó ÁõÈıºÀÌ´Ù. °¡Àå ÈçÇÑ ¼Òȱâ ÁúȯÀ̸ç(Àü¼Òȱâ ȯÀÚÀÇ 70~80%) °¡Àå ÈçÇÑ Áúº´(Àüü Àα¸ÀÇ ¾à 20%)ÀÌ´Ù. ¿©¼ºÀÌ ³²¼º¿¡ ºñÇØ 2¹è Á¤µµ ¸¹ÀÌ ¹ß»ýÇϸç 30´ë ¹× 40´ë¿¡¼ È£¹ßÇÏ°í ¼±Áø °ø¾÷±¹¿¡¼ ¸¹ÀÌ ¹ß»ýÇÑ´Ù. Áø´ÜÀ» À§Çؼ´Â º´·Â ûÃë°¡ °¡Àå Áß¿äÇÏ°í °¢Á¾ °Ë»ç·Î¼ ±âÁúº´À» Á¦¿ÜÇØ¾ß ÇÑ´Ù. Ä¡·á·Î´Â ¾ÈÁ¤¿ä¹ý(Á¤½Å°úÀû ¸é´ã ¹× ½É¸®¿ä¹ý, ½Å°æ¾ÈÁ¤Á¦), ½Ä»ç¿ä¹ý(°í¼¶À¯Áú À½½Ä ¼·Ãë, Àڱؼº À½½Ä ÇÇÇϱâ), ¾à¹° ¿ä¹ý(âÀÚ°æ·Ã ÁøÁ¤Á¦, º¯ºñ ¿ÏÈÁ¦, Áö»çÁ¦) µîÀ» »ç¿ëÇÑ´Ù. |
||
| ¿µ¹® | withdrawal syndrome | ÇÑ±Û | ±Ý´ÜÁõÈı٠|
|---|---|---|---|
| ¼³¸í | ¾ËÄÚ¿Ã, ¸¶¾à, ¹ÙºñÅõ¸£»ê°è ÃÖ¸é¾à µîÀÇ ¾à¹°À» Àå±â°£ º¹¿ëÇÏ¿© ¾à¹°ÀÌ ¾øÀÌ´Â °ßµô ¼ö ¾ø°ÔµÈ µÚ, ±× ¾à¹°À» ÁßÁöÇÑ °æ¿ì¿¡ ³ªÅ¸³ª´Â, °íÅëÀÌ ¼ö¹ÝµÇ´Â ½ÅüÀû Áõ»óÀ» ¸»ÇÑ´Ù. ¿¬¼Ó º¹¿ëÀÇ ±â°£¿¡ µû¶ó Áõ»óÀÌ ¹«°Å¿öÁø´Ù. Åë»óÀûÀ¸·Î ±¸Åä, ¼³»ç, Ç÷¾Ð»ó½Â, ºü¸¥¸Æ, ¶¡³², È¥¼ö µîÀÇ Áõ»óÀÌ ³ªÅ¸³´Ù. |
||
| ¿µ¹® | organic brain syndrome | ÇÑ±Û | ±âÁúÀû ³úÁõÈıº |
|---|---|---|---|
| ¼³¸í | ³úÀÇ ±âÁúÀûÀÎ(organic-:ÀÌ ¸»Àº ±â´ÉÀûÀÎ(functional)¿¡ ¹ÝÇÏ´Â ¸»·Î½á) ¸ðµç °Ë»ç¸¦ ½ÃÇàÇÏ¸é ¾î¶² ÀÌ»óÀ» ¹ß°ßÇÒ ¼ö ÀÖ´Ù´Â ¶æÀÌ´Ù. ¹Ù²Ù¾î ¸»Çϸé, ±â´ÉÀûÀÎ ÀÌ»ó¿¡ ÀÇÇÑ ³úÁõÈıºÀº ¾î¶°ÇÑ °Ë»ç·Îµµ ÀÌ»óÀ» ¹ß°ßÇÒ ¼ö ¾øÀ¸³ª ºÐ¸íÈ÷ ȯÀÚ¿¡°Ô ÀÌ»óÁõ»óÀÌ ³ªÅ¸³µÀ» ¶§ À̸¦ ¹¾î¼ ¸»ÇÑ´Ù. ÀÌ»ó¿¡ ÀÇÇØ ½Å°æÇÐÀûÀÎ ÀÌ»óÀ» ³ªÅ¸³»´Â ÀÏ·ÃÀÇ º´ÀûÇö»óÀ» ¸ðµÎ ÅëÆ²¾î ¸»ÇÑ´Ù. ÀÌ º´Àº ÈçÈ÷ º¸¾Æ ¸¶Ä¡ Á¤½Åº´È¯ÀÚó·³ ¸»À» Ⱦ¼³¼ö¼³Çϰí, ¾Ë¾ÆµéÀ» ¼ö ¾ø´Â ¸»À» Çϸç, ¶§·Î´Â ´Ù¸¥ »ç¶÷¿¡°Ô °ø°ÝÀûÀÎ ¼ºÇâÀ» ³ªÅ¸³»±âµµ ÇÑ´Ù. ±×¸®°í ´Ù¸¥ »ç¶÷°ú µµÀúÈ÷ ±³·ù¸¦ ÇÒ ¼ö ¾ø´Â Á¤¼¸¦ ³ªÅ¸³»±âµµ ÇÑ´Ù. ±×·¯³ª, ÀÌ º´ÀÌ ´Ù¸¥ Á¤½Åº´°ú ±¸º°µÇ´Â Ư¡ÀûÀÎ Áõ»óÀº ¸ÕÀú, ÀǽÄÀÇ È¥Å¹ÀÌ µ¿¹ÝµÇ´Â °æ¿ì°¡ ¸¹°í, ¶ÇÇÑ ±× Áõ»óÀÇ Á¤µµ°¡ º¯ÇÑ´Ù´Â °ÍÀÌ´Ù. Áï, ¾ÆÄ§¿¡´Â Á¤»óÀûÀÎ ÇൿÀ» ÇÏ´Ù°¡ ¿ÀÈİ¡ µÇ¸é, ÀǽÄÀÌ Èå·ÁÁö¸é¼ ¸»À» Ⱦ¼³¼ö¼³ÇÑ´Ù¸é, ÀÌ´Â ±âÁú¼º³úÁõÈıºÀÏ °¡´É¼ºÀÌ ³ô´Ù. |
||
| MM | macromolecule; Maelzels metronome; major medical [insurance]; malignant melanoma; manubrium to malle... |
|---|---|
| MS | Maffuci syndrome; maladjustment score; mandibular series; Marfan syndrome; Marie-Strumpell [syndrome... |
| CS | calf serum; campomelic syndrome; carcinoid syndrome; cardiogenic shock; caries-susceptible; carotid ... |
| PCS | palliative care service; Patient Care System; patterns of care study; pelvic congestion syndrome; ph... |
| FAMMM | familial atypical multiple mole-melanoma [syndrome] |
| WHHL | Watanabe Heritable Hyperlipidaemic |
|---|---|
| WHHL | Watanabe Heritable Hyperlipidemic Rabbit |
| ALM | Acral lentiginous melanoma |
| A-Mel-3 | Amelanotic melanoma |
| B16a | B16 amelanotic melanoma |
| heritable | Capable of being transmitted from parent to child. (12 Dec 1998) |
|---|---|
| acral lentiginous melanoma | <tumour> A form of malignant lentigo melanoma that occurs in acral areas not excessively exposed to sunlight and where hair follicles are absent. (05 Mar 2000) |
| amelanotic melanoma | <tumour> An anaplastic melanoma consisting of cells derived from melanocytes but not forming melanin. (05 Mar 2000) |
| benign juvenile melanoma | A benign, slightly pigmented or red superficial small skin tumour composed of spindle-shaped, epithelioid, and multinucleated cells that may appear atypical; most common in children, but also appearing in adults. Synonym: benign juvenile melanoma, epithelioid cell nevus, spindle cell nevus. (05 Mar 2000) |
| cancer, malignant melanoma | A skin cancer that begins in cells called melanocytes that can grow together to form benign (not cancerous) moles. A change in size, shape, or colour of a mole can be a sign of melanoma. Melanoma can be cured if detected early, before spread (metastasis) to other areas of the body. Diagnosis is confirmed with a biopsy of the abnormal skin. Sun exposure can cause skin damage that can lead to melanoma. (12 Dec 1998) |
| cancer, melanoma | A skin cancer that begins in cells called melanocytes that can grow together to form benign (not cancerous) moles. A change in size, shape, or colour of a mole can be a sign of melanoma. It can be cured if detected early, before spread (metastasis) to other areas. Diagnosis is confirmed by a biopsy of the abnormal skin. Sun exposure can cause skin damage that can lead to melanoma. (12 Dec 1998) |
| malignant lentigo melanoma | <tumour> A melanoma arising from a malignant lentigo. (05 Mar 2000) |
| malignant melanoma | <oncology, tumour> A malignant tumour which arises from the pigment producing cells (melanosomes) of the deeper layers of the skin (or the eye). Melanoma is the leading cause of death attributable to skin lesions. Described as an irregular dark skin lesion that may have areas of varying colour. Often greater than 6 mm in diameter. (27 Sep 1997) |
| malignant melanoma: gallium imaging | <radiology> Greater than50% sensitivity for primary and metastatic sites: 73% sensitivity if lesion is greater than 2 cm, 17% sensitivity if less than 2 cm, see: gallium: indications malignant melanoma (12 Dec 1998) |
| malignant melanoma in situ | A melanoma limited to the epidermis and composed of nests of atypical melanocytes and scattered single cells extending into the upper epidermis; local excision is curative although the lesion, if untreated, may soon invade the dermis. Malignant lentigo may be considered a slowly progressive type of malignant melanoma in situ. (05 Mar 2000) |
| malignant melanoma: staging | <radiology> Clark staging: level I: all tumour cells above basement membrane (in situ), level II: tumour extends to papillary dermis, level III: tumour extends to interface between papillary and reticular dermis, level IV: tumour extends between bundles of collagen of reticular dermis, level V: tumour invasion of sucutaneous tissue (87% metastases) Breslow staging: thin: less than 0.75 mm depth of invasion, intermediate: 0.76 - 3.99 mm depth of invasion, thick: greater than 4 mm depth of invasion see: malignant melanoma (12 Dec 1998) |
| melanoma | <oncology, tumour> A tumour arising from the melanocytic system of the skin and other organs. When used alone the term refers to malignant melanoma. (18 Nov 1997) |
| melanoma, amelanotic | An unpigmented malignant melanoma. It is an anaplastic melanoma consisting of cells derived from melanoblasts but not forming melanin. (12 Dec 1998) |
| melanoma growth stimulatory activity | Cytokine of the C X C subfamily. Potent mitogen. Activates and is chemotactic for, neutrophils. (18 Nov 1997) |
| minimal deviation melanoma | <dermatology, tumour> A malignant melanoma showing less cytologic atypia than is usual in melanoma cells showing asymmetric expansile invasion of the dermis. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|